Objective: To determine the total blood loss and hidden blood loss associated with surgery for lumbar spinal stenosis and to identify risk factors for blood loss.
Methods: From September 2002 to July 2006, the clinical data from 138 patients with lumbar spinal stenosis undergoing initial operation were analysed prospectively. There were 44 males and 94 females, aging 56-78 years (mean 66.7 years). A simple posterior lumbar spinal decompression was used in 26 cases; posterior spinal canal decompression, interbody distraction Cage, and bone graft between transverse process was used in 54 cases; pedicle screw fixation, posterior decompression and bone graft between transverse process was used in 32 cases; posterior decompression, pedicle screw fixation, interbody Cage, and graft between transverse process was used in 26 cases. Before operation, 23 patients took aspirin, and after operation 15 patients had gastrointestinal bleeding. Intraoperative blood loss was calculated by the aspirator and observed blood loss intraoperation. The whole estimated blood loss was calculated according to the level of hemoglobin, blood volume and blood transfusion at the time of admission and after 3 and 4 days of operation.
Results: The blood loss intraoperation was (485.51 +/- 143.75) mL. The estimated blood loss was (1218.60 +/- 306.86) mL, which was significantly higher than the intraoperational blood loss (P < 0.001). There was significant difference between the estimated blood loss and observed blood loss during surgeries (P < 0.001). There were significant differences in the estimated blood loss and observed blood loss during surgery between patients treated with aspirin and without aspirin (P < 0.001), between patients with gastrointestinal bleeding and whiout gastrointestinal bleeding (P < 0.001).
Conclusion: The total blood loss after surgery for lumbar spinal stenosis is much greater than that of observed intra-operation. The type of surgery, treatment with aspirin and gastrointestinal bleeding or ulceration can all independently increase blood loss.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A practical review of iron deficiency in pregnancy.
Semin Fetal Neonatal Med
March 2025
Department of Obstetrics and Gynecology, Intermountain Health, Murray, UT, USA; Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, UT, USA. Electronic address:
Iron deficiency is a highly prevalent nutritional deficiency and the most common cause of anemia worldwide. Pregnant individuals are particularly susceptible due to increased demands to support expanding maternal blood volume and fetal growth. Iron deficiency and iron deficiency anemia are associated with maternal and neonatal morbidity, including preterm birth, preeclampsia, postpartum hemorrhage, and low birth weight.
View Article and Find Full Text PDFGeneration of Dual-Color FISH probes targeting 9p21, Xp21, and 17p13.1 loci as diagnostic markers for some genetic disorders and cancer in Egypt.
J Genet Eng Biotechnol
March 2025
Human Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Egypt.
Introduction: The fluorescence in situ hybridization (FISH) is a very important technique, as it can diagnose many genetic disorders and cancers. Molecular cytogenetic analysis (FISH) can diagnose numerical chromosome aberrations, sex chromosomes anomalies, and many genetic disorders.
Aim: With the limited number of commercially available probes that do not cover all research needs and the high prices of the commercial probes, our goal is to apply recent technologies to produce FISH probes that can accurately and sensitively diagnose genetic diseases and cancer in Egypt and establishing the inhouse production of different FISH probes.
Blue rubber bleb nevus syndrome: A case report and literature review.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
October 2024
Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Blue rubber bleb nevus syndrome (BRBNS) is a rare congenital clinical syndrome characterized by venous malformations in multiple organs, including the skin, gastrointestinal tract, liver, and lungs. In June 2022, Third Xiangya Hospital of Central South University admitted a rare case of BRBNS. The patient was hospitalized due to abdominal distension and a history of recurrent hematochezia.
View Article and Find Full Text PDFVolume-targeted on high-frequency oscillatory ventilation in preterm infants: a systematic review.
J Pediatr (Rio J)
March 2025
Hospital das Clínicas de Ribeirão Preto da Universidade de São Paulo, Departamento de Pediatria, Divisão de Terapia Intensiva Neonatal, Ribeirão Preto, SP, Brazil.
Objective: This systematic review aimed to analyze, in neonates, the effects of high-frequency oscillatory ventilation (HFOV) with volume-targeted (VT) compared with conventional HFOV.
Sources: The authors searched PubMed, EMBASE, Cochrane, and ClinicalTrials.gov from inception until August 4th, 2024, to identify studies comparing HFOV with and without VT in neonates under 44 weeks corrected age.
Preclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models.
J Control Release
March 2025
Clinical Biochemistry, Drug Delivery and Therapy Group (CB-DDT), Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain; Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; Department of Pharmacy and Pharmaceutical Technology and Physicochemistry, Faculty of Pharmacy and Food Sciences, School of Pharmacy, Universitat de Barcelona (UB), Av. de Joan XXIII, 27-31, 08028 Barcelona, Spain. Electronic address:
Glioblastoma multiforme (GBM) is one of the most lethal cancers, with limited treatment options due to the blood-brain barrier (BBB), systemic toxicity, and treatment resistance. Nanomedicine offers potential solutions to these challenges. This study explores Pluronic® F127 and Soluplus®-based micelles as carriers for Lomustine, Gefitinib, and Docetaxel to determine the optimal system for GBM therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!